AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05254171 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study NCT06277401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular training for the knee
Description: The exercise programme includes exercises identified in literature to target muscles around the knee.
Study NCT06277401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-load strength training for the knee
Description: The exercise programme includes exercises identified in literature to target muscles around the knee.
Study NCT06333717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole grain bread
Description: Consumption of high-fibre bread as a dietary supplementation
Study NCT06333717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control bread
Description: Consumption of control bread as a dietary supplementation
Study NCT06167525 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Real-time feedback through the device. Bio-feedback signals will be given once deviated from a neutral posture for >1 minute. Response of surgeons to bio-feedback signals will be recorded
Description: During the first stage of the study the device will be set to record cervical spine positioning without bio-feedback signals. This will be used to record duration of time surgeons held maladaptation postures.~The second stage will involve real-time feedback through the device. For surgeons who consent, bio-feedback signals will be given once deviated from a neutral posture for >1 minute. Response of surgeons to bio-feedback signals will also be recorded.~The Neck Disability index score will be used to assess for neck pain and the functional implications in relation to reported neck pain. This will be completed following study completion.
Study NCT05500664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lavender Oil
Description: three drops of the designated lavender will be placed on a 2-inch by 2-inch impermeable, backed gauze pad and patient was asked to inhale deeply for 5 minutes
Study NCT04576741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bMBI shorter more frequent practice
Description: This is a 12-week online mindfulness-based course blended with therapist support via video link using shorter, more frequent practice than standard Mindfulness-Based Cognitive Therapy (2x15-minutes/day).
Study NCT06363630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Specified dose on specified days.
Study NCT06363630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Specified dose on specified days
Study NCT06363630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golcadomide
Description: Specified dose on specified days
Study NCT04959383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low complexity Exergaming group
Description: This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept low for this group.
Study NCT04959383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate complexity Exergaming group
Description: This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept moderate for this group.
Study NCT04959383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High complexity Exergaming group
Description: This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept high for this group.
Study NCT04959383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. This group will receive exergame balance training on Wii fit. Participants in this group will play Soccer Heading, Ski Slalom, Ski Jump, Table Tilt, Tightrope Walk, Balance Bubble, Penguin Slide and Snowboard Slalom game.
Study NCT05813938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LabTest Checker
Description: A set of blood laboratory tests is ordered. Test results are recorded in the LabTest Checker. LabTest Checker's diagnostic engine automatically generates a personalized questionnaire that is filled out by the patient. After obtaining all necessary information, including the patient's chronic diseases, medications taken, and symptoms, the tool presents an interpretation of test results.
Study NCT04837027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Aerobic training on stationary bike 5x a week for 30 minutes a day
Study NCT04837027 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance training
Description: Training 5x a week for 30 minutes. Standard of care
Study NCT06586151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendent Health
Description: Gender-inclusive HIV prevention program: Text messaging-based program that lasts 5 months. Content includes information, motivation and behavioral skills about how to prevent HIV, as well as information about healthy and unhealthy romantic relationships, and navigating issues related to one\&#39;s gender.
Study NCT06586151 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Text Messaging with Information
Description: Text messaging-based program that lasts 5 months. Content includes information about HIV prevention and aspects of a healthy adolescent lifestyle (e.g., self-esteem).
Study NCT06601621 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: electroacupuncture+ self-acupressure
Description: Participants will receive two electroacupuncture treatments within the first week of each treatment cycle. The acupuncturist inserts the needle into the point and manipulates the needle until the feeling of deqi; is achieved and reported by the participant. The electrical stimulation will be administered at a sustained frequency of 2/10Hz for 30 minutes. self-acupressure: In weeks 2 and 3 of each treatment cycle, participants performed true self-administered acupressure, pressing each acupoint with their thumb to achieve deqi; for three minutes.
Study NCT06601621 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: sham electroacupuncture + sham self-acupressure
Description: Sham electroacupuncture: The sham electroacupuncture shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive acupuncture treatment without electrical stimulation same the intervention group. And avoid deqi; sensation. Sham self-acupressure: Administered non-acupressure points 1 to 3cm away from the true acupressure points used in the experimental group and away from known meridians. The frequency, course duration, and overall treatment time will be the same as those in the true self-administered shiatsu group. The applied pressure does not cause a feeling of deqi.
Study NCT04686227 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3D Ultrasound
Description: Newly married women between the ages of 18-40 will be evaluated by 3D ultrasonography about the uterine morphology
Study NCT05481697 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GRAIL Galleri
Description: A blood test that aims to detect cancers earlier by looking for abnormal DNA shed from cancer cells into the blood.
Study NCT06589986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7790121
Description: RO7790121 will be administered as IV infusion. RO7790121 will be administered as SC injection.
Study NCT06589986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching IV RO7790121. Placebo matching SC RO7790121.
Study NCT06614660 — intervention group
Intervention type: OTHER
Intervention: Metabolism genomics and imaging genomics
Description: Pre-operative imaging images of the patient were collected prior to surgery, and 2 ml of the patient\&#39;s blood specimen was collected to collect metabolism genomics and imaging genomics.
Study NCT06480864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab Injection
Description: Adebrelimab injection (1200mg) will be administered by intravenous infusion during the induction phase and maintenance phase on day 1 in a 3-week treatment cycle.
Study NCT06480864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate Tablets
Description: Apatinib mesylate tablets (250 mg) will be administered orally in a 3-week treatment cycle, once a day.
Study NCT06480864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (AUC 4-5mg/mL/min) intravenous infusion will be administered during the induction phase on day 1 in a 3-week treatment cycle.
Study NCT06480864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (75mg/m2) intravenous infusion will be administered during the induction phase on day 1 in a 3-week treatment cycle.
Study NCT06480864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide(100mg/m2) intravenous infusion will be administered during the induction phase from day 1 to 3 in a 3-week treatment cycle.
Study NCT06370936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized diet with commercially available animal meats (comparator products)
Description: Fully controlled standardized diet with commercially available meats from animal origin. Fully controlled means that all food products 8-week intervention will be provided by the HNRU at Wageningen University. The standardized diet is designed to maintain body weight, and follows the average nutritional pattern of middle-aged men and women in the Netherlands, while taking individual habitual energy intake into account. The diet will have the same dietary composition for each person and energy intake will be based on the energy requirements of an individual. The diet is the same for both intervention periods, except for the origin of meat products: PBMAs versus meat of animal origin.
Study NCT06370936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized diet with commercially available PBMAs (intervention products)
Description: Fully controlled standardized diet with commercially available Plant-Based Meat Analogues (PBMAs). Fully controlled means that all food products 8-week intervention will be provided by the HNRU at Wageningen University. The standardized diet is designed to maintain body weight, and follows the average nutritional pattern of middle-aged men and women in the Netherlands, while taking individual habitual energy intake into account. The diet will have the same dietary composition for each person and energy intake will be based on the energy requirements of an individual. The diet is the same for both intervention periods, except for the origin of meat products: PBMAs versus meat of animal origin.
Study NCT05255913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanosilver
Description: preventive material for arresting caries
Study NCT05255913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver diamine fluoride
Description: preventive material for arresting caries
Study NCT06552507 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duroplasty
Description: The investigators open the dura from midline and repaired with fish mouth for dura augmentation
Study NCT06154031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyad learning
Description: All participants will perform a gamified exercise using a dyad learning protocol. This means that all participants will practice the gamified exercise in pairs (dyads), for 60 minutes on two consecutive days.
Study NCT04296526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Prescription
Description: To prescribe exercise programs that can be easily applied at home/dormitory/living place for students.
Study NCT04296526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Education
Description: To organize sessions for how to proper exercise.
Study NCT04296526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: Supports such as peer influence or reminder phone messages
Study NCT05524870 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization
Description: Movement with mobilization plus exercise
Study NCT05524870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization
Description: Movement with mobilization plus exercise
Study NCT05524870 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mobilization
Description: Movement with mobilization plus exercise
Study NCT05515822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Hydrochloride
Description: The doses were calculated according to the ideal body weight. Oxycodone was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
Study NCT05515822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dezocine
Description: Dezocine was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
Study NCT05515822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine and Oxycodone
Description: Esketamine was administered 5min before skin incision, and Oxycodone was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
Study NCT06616571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL0605(PEG-rhG-CSF)
Description: Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 24 hours s.c. post chemotherapy application.
Study NCT06616571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QL0605(PEG-rhG-CSF)
Description: Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 24 hours s.c. post chemotherapy application.
Study NCT06616571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL0605(PEG-rhG-CSF)
Description: Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 48 hours s.c. post chemotherapy application.
Study NCT06616571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QL0605(PEG-rhG-CSF)
Description: Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 48 hours s.c. post chemotherapy application.
Study NCT06615791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIT FIRST Teen
Description: High intensity sports drills and games.
Study NCT06617442 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: First pulmonary vein isolation performed for atrial fibrillation.
Study NCT06617442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Description: First pulmonary vein isolation performed for atrial fibrillation.
Study NCT05039476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Retinol face cream
Description: Retinol face cream
Study NCT05039476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo face cream
Description: Placebo face cream
Study NCT06631729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV-bio
Description: participants will complete a HRV biofeedback task via the Elite HRV app. In this intervention, participants will learn how to use their HRV data that they will see in real-time via the Elite HRV app to improve their HRV by engaging in an app-guided diaphragmatic breathing exercise. They will complete this exercise twice daily (morning, night).
Study NCT06631729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ED-JITAI
Description: participants will be prompted to complete focused, guided body scan tasks that will be sent to them via the MindLogger app. These guided tasks will be sent to them in the form of 1 of 3 brief (3-5 minute) videos via the MindLogger app. The body scans will be designed to promote participants' connection with, vs.~distancing/distraction from, feared ED sensations (e.g., hunger, satiety, bloating).~Participants will receive prompts to complete the body scans at times when they report via EMA that they are experiencing worse interoception than usual. Worse interoception than usual will be defined as participants' EMA-reported interoception scores during the intervention period that fall 1 SD or more above their baseline EMA-reported interoception levels.
Study NCT03496883 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Activated Factor VII (rFVIIa)
Description: Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.
Study NCT03496883 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.
Study NCT06081686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I:[177Lu]Lu-XT033 Injection
Description: Six subjects were enrolled in the 1.11 Gbq (30 mCi) group of \[177Lu\] Lu-XT033 Injection. The last subject in this group completed the 4-week observation period after the first dose, With the consent of the Safety Monitoring Committee (SRC), 6 subjects were enrolled in the 1.85 Gbq (50 mCi) group. Both groups used 8 ± 1 weeks as the dosing interval .
Study NCT06081686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II:[177Lu]Lu-XT033 Injection
Description: Patients received \[177Lu\]Lu-XT033 Injection every 8 weeks (+/- 1 week) for a maximum of 6 cycles.
Study NCT06393244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a theory-based home-based multi-component exercise training
Description: The participants in the intervention group will receive a 12-week theory-based home-based MCE program, which consists of three phases: exercise mobilization phase, exercise preparation phase (exercise instructions and exercise plan determination), and home-based autonomous exercise training. Structured guidelines have been developed for the intervention by the research team. This allowed interveners to deliver the intervention in a structured way with the same dosage.
Study NCT04367415 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Darwish test for a free endometrial cavity
Description: Darwish test (Office hysteroscopic bubble suction and tubal peristalsis). If the uterine cavity is normal the patient will be allocated as group A
Study NCT04367415 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Darwish test for an endometrial cavity with endometrial polyps
Description: Darwish test (Office hysteroscopic bubble suction and tubal peristalsis).If there is one or more polyp(s) the patient will be allocated as group B.
Study NCT06358937 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Assisted New Attachment Procedure using ND:YAG laser
Description: A free running, pulsed, 1064 nm wavelength-specific ND:YAG laser will be used. A thin 300 μm laser fiber optic will be placed parallel to the root surface, allows easy access into deep periodontal pockets. The initial pass with the laser is known as Laser Troughing, and it is done with a micro-short duration pulse, with a 4.0 watt power, 150 μs duration in pulsed mode and 20Hz frequency. Ultrasonic scaler will be then used to remove calculus. The second pass is carried out with 650 μs pulse duration, 10-30 seconds for each tooth, 4.0 watt power and 20HZ frequency, to improve the ability to generate a fibrin clot. The fibrin clot is then compressed. Relieving the occlusion is the last step of the LANAP protocol.
Study NCT06358937 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Assisted New Attachment Procedure using diode laser
Description: Diode laser (Biolase) with 940 nm wavelength, a thin flexible fiber-optic cable 300 μm attached with a power average set at 0.5-1.5 watt will be used.~The first pass laser troughing is done using a thin flexible fiber-optic cable 300 μm placed parallel to the root surface, attached with a power average set at 0.5-1 watt, in continuous mode. Ultrasonic scaler will be then used to remove calculus which present on the root surface. The second pass is carried out with 1-1.5 watt power in continuous mode, 10-30 seconds for each tooth, and, to improve the ability to generate a fibrin clot. The fibrin clot is then compressed in order to enhance the healing